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Abstract
Multidrug resistance (MDR) in cancer poses a major
obstacle to the success of chemotherapy. We
previously reported that cyclic AMP (cAMP)-resistant
mutants of the Chinese hamster ovary and the mouse
adrenal cortical carcinoma cells harboring defective
regulatory (RIo) subunits of the cAMP-dependent
protein kinase (PKA) are more sensitive than wild-type
cells to chemotherapeutic agents that are substrates
for P-glycoprotein. In addition, a transfectant
overexpressing a mutant RIa cDNA showed similar
increased sensitivity to these drugs. The altered drug
sensitivity in the RIa mutants results from reduced
expression of the mdr gene, suggesting that PKA may
regulate its expression. In this study, we evaluated the
sensitivity of several Chinese hamster ovary catalytic
(C) subunit mutants to various anticancer drugs. Like
the RIa subunit mutant, the C subunit mutants also
exhibit decreased kinase activity and unresponsiveness
to growth inhibition by cAMP. However, in contrast to
the Rla subunit mutant, the C subunit mutants are not
multidrug sensitive and maintain P-glycoprotein
expression levels comparable to those of wild-type
cells. Furthermore, the C subunit mutants display the
same resistance patterns as wild-type cells to P-
glycoprotein substrates, including Adnamycin, Taxol,
and colchicine. No significant difference was observed
in their sensitivity to non-MDR drugs, such as 5-
fluorodeoxyuridine, between wild-type, RIa, and C
subunit mutant cells. These results suggest that the
increased multidrug sensitivity in the PKA mutant cells
results from alteration of the Rla subunit and not the
kinase activity, thus implying novel functions for the
Rla subunit. Therefore, genetic alteration of the RIa
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subunit of PKA may modulate drug resistance in
cancer.
Introduction
Emergence of MDR3 is a serious problem in cancer chemo-
therapy because tumors become refractory to treatment with
a variety of natural product anticancer agents that are both
chemically and physically unrelated. This increased resist-
ance to multiple cytotoxic drugs is due to overexpression of
the mdr gene, which encodes a plasma membrane ATP-
dependent drug efflux pump termed P-glycoprotein. The
resultant resistance limits the choice of cytotoxic agents that
are available for chemotherapy and leads to treatment failure
(1-3).
Expression of the MDR1 gene occurs commonly in human
cancers, and its regulation has been actively investigated in
recent years (4-6). It has been shown that the CHO and the
mouse adrenal corticocarcinoma Yl cells harboring a defec-
tive RIo subunit of the cAMP-dependent PKA are sensitive to
multiple chemotherapeutic drugs that are substrates for P-
glycoprotein (7). In addition, a transfectant overexpressing a
dominant mutant RIa cDNA shows similar increased sensi-
tivity to these drugs (8). We have shown subsequently that
the increase in drug sensitivity is due to decreased expres-
sion of the mdr gene in these mutants (9). Therefore, an intact
PKA system is apparently required for maintaining the basal
levels of mdr RNA in these cells. The role of PKA in P-
glycoprotein expression was further supported by the dis-
covery that a selective inhibitor of PKA, H-87, inhibited
MDR1 gene expression and promoter activity in the mouse
P388 cells (10). These studies suggest that alteration of PKA
activity may modulate cellular sensitivity to chemotherapeu-
tic agents and establish that the cAMP signal transduction
pathway may be involved in regulating drug resistance.
To provide further evidence that changes in drug sensitiv-
ity are due to alteration of PKA activity, we examined in this
study the sensitivity of CHO cells with mutations in the C
subunit of PKA to various chemotherapeutic agents that are
substrates for P-glycoprotein. Despite their cAMP-resistance
and decreased kinase activity, the C subunit mutants main-
tamed the same drug resistance patterns as the wild-type
cells, whereas the Rkr subunit mutants displayed increased
sensitivity to these cytotoxic agents. Furthermore, P-glyco-
protein levels in the C subunit mutants were comparable to
wild-type levels but were reduced in the R subunit mutants.
These results suggest that decreased mdr gene expression
in the R subunit mutants may be a direct result of the mu-
3 The abbreviations used are: MDR, multidrug resistance; CHO, Chinese
hamster ovary; A, regulatory; C, catalytic; PKA, cAMP-dependent protein
kinase; 8-Br-cAMP, 8-bromo-cAMP; RI, regulatory subunit of type I PKA;
RIa, alpha subtype of RI; RIl, regulatory subunit of type II PKA.
Table 1 Effect of cAMP on cell cycle distribution of wild-type and PKA
mutant cellsa
Approximately 1 x 106 cells were plated in 100-mm dishes and incu-
bated with or without 1 mi 8-Br-cAMP for 24 or 48 h. After fixation in 70%
ethanol, cells were stained with a 10-.tg/ml propidium iodide/i mg/mi
RNase/PBS solution, and the DNA content of the cells was analyzed by a
FACScan flow cytometer. Cell cycle data analysis was performed with the
ModFit LT program.
24h 48h
Cell type -- ---  ---   -  
Without cAMP With cAMP Without cAMP With cAMP
i000i 22 50 58 79
10248 24 23 56 5i
i02i5 47 48 76 73
10260 48 49 65 66
10265 48 53 72 74
a Data presented are based on at least three independent experiments
performed in duplicate. Numbers denote the percentage of cells in G0-G1.
1








Fig. 1. PKA activity in wild-type and mutant CHO cells. PKA activation
was measured relative to 1 00% activation of the wild-type at 100 .tM
cAMP. All values were corrected for activity in the absence of cAMP.
Columns, average of three separate experiments repeated in duplicate.
10001, wild-type; 10248, Rk subunit mutant; 10215, 10260, and 10265,





tation in the Ria subunit gene rather than altered kinase
activity. These genetic studies with the PKA mutants imply
that the Rla subunit of PKA may have other cellular functions
in addition to inhibiting the kinase activity of the C subunit
and that mutation of the Rki subunit may directly affect drug
resistance in cancer.
Results
Analysis of genetic mutants in the cAMP signal transduction
pathway has increased our understanding of the role of
cAMP and PKA in the modulation of cellular processes. The
pioneering approach of Tomkins and colleagues (1 1 , 12) in
developing the mutant genetic systems with the mouse S49
lymphoma cells through a combination of mutagenesis and
exploitation of their growth characteristics in cAMP permit-
ted the isolation and selection of mutant cells that do not
respond to cAMP. On the basis of this approach, the CHO
cells used in the present study have impaired PKA activity
resulting from mutations in either the R or the C subunit gene
of PKA (13, 14). The 10248 mutant cells contain a dominant
mutation (glycine to glutamic acid substitution at amino acid
200) in the cAMP-binding domain of the RIa subunit that
decreases its affinity for cAMP and prohibits holoenzyme
dissociation (1 5, 1 6). Consistent with previously reported
results (15, 16), the Rla mutants have a 50% reduction in
PKA activity in comparison to the wild-type 1 0001 cells (Fig.
1). Mutants with altered C subunits (10215, 10260, and
1 0265) have decreased affinity for ATP and decreased pro-
tein substrate specificity (14, 1 7-1 9). Again, consistent with
previous results, C subunit mutants 10215, 10260, and
1 0265 have residual kinase activities in the amount of 51 , 13,
and 17% of the wild-type control, respectively (Fig. 1). Ex-
pression of the RI subunit seemed to be comparable be-
tween wild-type cells and the mutants by Western blot anal-
ysis (data not shown).
Fig. 2. P-gtycoprotein expression in KB and CHO cells. Cell extracts
(100 g of protein) from KBV-1 cells that overexpress P-glycoprotein,
KB3-1 cells that are MDR1-null mutants, and CHO cells were run on a 6%
denaturing polyacrylamide gel. Protein was transferred to a polyvinylidene
difluoride membrane and probed with 1 g/ml C219 monoclonal antibody
for 12 h. The immunoreactive bands were detected by use of an ECL kit
using a secondary goat antimouse antibody conjugated to horseradish
peroxidase. A representative of four separate experiments is shown.
It has been shown that mutations affecting the R or C
subunit of PKA caused an increase in resistance to the
growth inhibitory effects of cAMP in CHO cells (13, 20).
Consequently, activation of the mutant PKA in these cells
requires much higher concentrations of the second messen-
ger. Cell cycle analysis of the PKA mutants by flow cytometry
confirmed this cAMP-resistant phenotype observed previ-
ously. Treatment with 1 m 8-Br-cAMP did not significantly
alter the cell cycle patterns of the Rla and C subunit mutants
after 24 or 48 h (Table 1). However, a G1 growth arrest was
observed with the wild-type cells 24 h after exposure to 1 mri
8-Br-cAMP. A further increase in C1 block was observed in
1 0001 cells after 48 h of treatment (79% of the cell popula-
tion in G1 after treatment versus 58% of the untreated con-
trol). These results confirmed that the PKA mutants are re-
sistant to the growth inhibitory effects of cAMP.
We reported previously that the RIa subunit mutants have
decreased mdr gene expression, and this reduced P-glyco-
protein expression was thought to be associated with altered
kinase activity (8, 9). Therefore, it was expected that the C
subunit mutants suffering from a similar loss in PKA activity
would also have altered P-glycoprotein expression. Surpris-
ingly, Western blot analysis showed that the C subunit mu-
tants have levels of P-glycoprotein expression comparable
to those of the wild-type 10001 cells (Fig. 2). Consistent with
previous results (8, 9), a 50% reduction in P-glycoprotein
expression was observed in the 1 0248 Rkx mutant. Densito-
[Adriamycini (nglml) [Coichicine] (ng/mI)
[Taxol] (ng/ml) [5-Fluorodeoxyuridinej (jiM)
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Fig. 3. Sensitivities of CHO cells
to substrates of P-glycoprotein.
Exponentially growing cells were
plated in 60-mm dishes and ex-
posed to various concentrations of
the MDR substrates Adriamycin
(A), colchicine (B), and Taxol (C).
After approximately 7-1 0 days,
surviving colonies were stained
with methylene blue and scored.
LI, wild-type CHO cells; #{149},#{149},A,
and U, PKA A and C subunit mu-
tant derivatives. 0, cell survival of
CHO cells after treatment with the
non-MDR drug 5-fluorodeoxyuri-
dine. P < 0.02 was compared with
the value for wild-type 10001 cells
in all results analyzed. Results pre-
sented are the means from three
separate experiments.
metric scanning confirmed the altered levels of P-glycopro-
tein in the 10248 mutant cells (data not shown). Because mdr
gene expression was not altered in the C subunit mutants,
therefore, our results suggest that the altered expression
may be associated with the defective Ala subunit and not
decreased kinase activity.
We then further examined the changes in drug sensitivity in
these PKA mutants to various drugs that are substrates for
the multidrug transporter. As shown in Fig. 3, C subunit
mutants 10215, 10260, and 10265 exhibited the same pat-
tern of resistance as wild-type cells to Adriamycin, Taxol, and
colchicine. These results correlate with the level of P-glyco-
protein expression in wild-type and C subunit mutant cells.
Furthermore, consistent with earlier studies (7-9), the R sub-
unit mutants displayed increased sensitivity to these drugs.
There was no difference in the sensitivities of wild-type or R
or C subunit mutant cells to the non-MDR drug 5-fluorode-
oxyuridine (Fig. 3D). These data support the idea that muta-
tion in the RIa subunit of PKA contributes to the altered drug
sensitivity and suggest a novel function for the Ala subunit.
Discussion
Expression of P-glycoprotein has been shown to play a
significant role in the clinical resistance of a large variety of
human malignancies (21-23). Therefore, studies of the reg-
ulation of the mdr gene may yield novel insight into circum-
venting MDR in cancer. Previously, we showed that RIa
subunit mutants of CHO cells, as well as wild-type cells,
transfected with a dominant mutant Ala cDNA have reduced
mdr gene expression and display increased sensitivity to
chemotherapeutic agents that are substrates for P-glycopro-
tein (7, 9). These data suggest that alteration in P-glycopro-
tein levels may be regulated by PKA. Although nuclear
run-on assay results suggest that expression of mdr genes
may be posttranscriptionally regulated, the precise regula-
tory input of PKA remains undefined (9). To substantiate the
role of the kinase in the regulation of mdr gene expression,
we further evaluated, in the present study, the P-glycoprotein
levels and the cellular sensitivity of several C subunit PKA
mutants to anticancer agents. Despite their decreased PKA
activity (Fig. 1) and resistance to growth inhibition by cAMP
(like the R subunit mutants; Table 1), surprisingly, mutations
in the C subunit in 10215, 10260, and 10265 cells did not
alter their P-glycoprotein expression levels (Fig. 2). The C
subunit mutants also had MDR patterns comparable to wild-
type cells (Fig. 3, A-C). Moreover, wild-type and RIa and C
subunit mutants maintained the same sensitivity to non-MDR
drugs, including 5-fluorodeoxyuridine (Fig. 3D). Changes in
P-glycoprotein levels and altered drug sensitivity could not
have been due to changes in either PKA type I or PKA type
II activity because the mutants 1021 5 (missing type II but
retaining a reduced amount of type I activity; Ref. 15), 10265
(missing type I kinase but having reduced type II activity; Ref.
15), and 10260 (very little type I or type II activity; Ref. 19) all
exhibited patterns of resistance to Adriamycin, Taxol and
colchicine similar to those of wild-type cells. Therefore, there
appears to be no direct correlation between alterations in
type I and type II PKA activity and P-glycoprotein levels.
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These results support our hypothesis that decreased mdr
gene expression in 10248 cells may be a result of the mu-
tation in the Ala subunit gene and suggest that the RIa
subunit but not the C subunit kinase may modulate cellular
multidrug sensitivity.
Other recent studies lend further support for a function of
Ala in modulating drug sensitivity. It has been shown that
overexpression of the RIa subunit in CHO-KI cells via retro-
virus-mediated gene transfer increases their sensitivity to
topoisomerase II poisons (24). Furthermore, the CHO-KI-
derivative ADA-S mutant, which overexpresses the endoge-
nous Ala, is also hypersensitive to topoisomerase II inhibitors
and displays cross-sensitivity to the site-selective cAMP an-
alogue 8-Cl-cAMP (24). Although neither the kinase activity
nor P-glycoprotein levels were examined in these studies,
they demonstrate a relationship between Ala expression and
cellular sensitivity to drugs that target topoisomerase II. In
addition, it has been shown that treatment of the multidrug-
resistant human MCF-7 breast cancer and the A2780 ovarian
carcinoma cells with 8-Cl-cAMP leads to decreased MDR1
gene expression and increased vinblastine accumulation
(25). 8-Cl-cAMP has the ability to down-regulate Ala expres-
sion and activity (26). The down-regulation of Ala in MCF-7
and A2780 cells correlates with the decreased P-glycopro-
tein expression and enhanced cellular sensitivity in these
cells, suggesting a role for Ala in regulating MDR1 expres-
sion. Taken together, these findings seem to indicate that
changes in drug sensitivity may be due to genetic alterations
of the Ala subunit of PKA via mutation or altered gene
expression.
Our laboratory has also examined the role of PKA in the
development of drug resistance to cisplatin (27). We have
found that CHO and mouse adrenocortical carcinoma Yl
cells with defective Ala subunits but not altered C subunits
exhibit increased resistance to cisplatin. The Ala mutants are
also cross-resistant to other DNA-damaging agents, and
further analysis by the host cell reactivation assay revealed
an enhanced DNA repair capacity in these mutants. We
speculate that the altered resistance may be a function of the
Ala subunit, as opposed to the activity of the kinase (27).
Furthermore, a study examining the effects of 8-Cl-cAMP on
parental and cisplatin-resistant PC-i 4 non-small cell lung
cancer cell lines showed a correlation between a low RI:RII
ratio and increased resistance to cisplatin, supporting the
idea that Ala deregulation is specific to cisplatin resistance
(28).
The precise mechanisms by which Ala modulates drug
resistance are unclear at present. It is conceivable that Ala
may interact with other proteins that subsequently alter cel-
lular sensitivity to cytotoxic agents. For example, the All
subunit of PKA has been found to associate with the A-ki-
nase anchor protein AKAP7O, demonstrating that the A sub-
unit can interact with other proteins (29). Furthermore, the
phosphorylated All subunit has been shown to interact with
DNA and to possess DNA relaxing activity (30). Therefore,
the A subunit may have the ability to positively or negatively
regulate factors involved in cellular drug resistance via pro-
tein-protein interaction or posttranslational modification.
Certainly, our results and those of others suggest that the
Ala subunit of PKA may have other cellular functions in
addition to inhibition of the kinase activity and that mutation
of the Ala subunit may affect drug sensitivity in these cells.
Therefore, exploitation of the cAMP levels and the A subunit
function may potentiate the cytotoxicity of chemotherapeutic
agents and reduce drug resistance in cancer. More impor-
tantly, the drug resistant phenotypes and their mechanisms
may enable us to begin to examine potentially novel regula-
tory functions of the RIa subunit.
Materials and Methods
Cell cultur. and Drug SensitMty Assays. CHO and KB cells were
cultured in a-MEM and DMEM, respectively, supplemented with 10% fetal
bovine serum, 2 mM glutammne, 50 units/mI penicillin, and 50 g of strep-
tomycin in a humidified atmosphere of 95% air and 5% CO2 at 37#{176}C.
Cytotoxicity was evaluated using the clonogenic assay. For clonogenic
survival, 200 cells were plated in 60-mm diameter Petri dishes and im-
mediately treated with various concentrations of drugs. After a 7-1 0 day
incubation, colonies were stained with methylene blue (0.01 g/ml in 50%
methanol), and colonies containing greater than 50 cells were scored.
Cell cycle Analysis and Flow Cytometry. Approximately 1 x 106
cells were plated in 100-mm dishes and incubated with or without 1 m
8-Br-cAMP (Sigma Chemical Co., St. Louis, MO) for 24, 36, or 48 h. After
fixation in 70% ethanol, cells were stained with a 10 jg/ml propidium
iodide/i mg/mI RNase/PBS solution, and the DNA content of the cells was
analyzed in duplicate by a FACScan flow cytometer (Becton Dickinson,
Mountain View, CA). Cell cycle data analysis was performed with the
MOdFit LT program (verity Software House, Inc., Topsham, ME).
Western Blot Analysis. For Westem blot analysis of P-glycoprotein
expression, protein lysates (100 p.g) were separated by 6% SDS-PAGE,
transferred to polyvinylidene difluonde membranes, and incubated for
12 h with 1 g/ml of the monoclonal antibody C219 against P-glycopro-
tein. The immunoreactive bands were detected by use of an ECL kit
(Amersham Corp., Arlington Heights, IL) using a secondary goat anti-
mouse antibody conjugated to horseradish peroxidase (Life Technologies,
Inc., Grand Island, NY).
PICA Activity Assay. Kinase activity was determined by measunng the
transfer of 32P from [y-32P]AW to Kemptide (Sigma), a specific substrate
for PKA(8). Cell extracts were prepared by homogenization in 10 m.i Tns,
pH 7.4, 0.8 mM EDTA, and 1 m DTT. Homogenates were centrifuged for
5 mm at 14,000 rpm. The reaction mixture contained 27.5 m Mes, 1 .0 mri
EDTA, 2.75 mM NaF, 5.5 m magnesium acetate, 1 .25 mg/mI BSA, 0.1 mg
Kemptide, 100 u,i ATP, 100 i CAMP, and 5.0 Ci [2P]AW in a total
volume of 0.1 ml. The reaction was initiated by the addition of cell extract
(80 g of protein). After 1 0 mm of incubation at 30#{176}C,40-pi aliquots were
immediately spotted on phosphocellulose discs (Whatman P81 filter pa-
per), washed four times with 3% phosphoric acid, and quantitated by
scintillation counting. A no-enzyme blank was subtracted from the total
incorporation, and all values were corrected for activity in the absence of
cAMP.
Statistics. Statistical significance was assessed where appropriate by
a paired Student’s t test (significant difference at P < 0.05).
Acknowledgments
We thank Dr. Michael M. Gottesman (National Cancer Institute, Bethesda,
MD) for the gift of the KB and CHO cell lines.
References
1 . Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance
mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-
427, 1993.
2. Endictoo, J., and Ling, v. The biochemistry of P-glycoprotein mediated
multidrug resistance. Annu. Rev. Biochem., 58: 137-1 71 , 1989.
3. Chin, K-V., Pastan, I., and Gottesman, M. M. Function and regulation
of the human multidrug resistance gene. Adv. Cancer Res., 60: 157-180,
1993.
Cell Growth & Differentiation 1247
4. Chin, K-V., Ueda, K., Pastan, I., and Gottesman, M. M. RAS and p53
modulate the promoter of the human multidrug resistance (MDR1) gene.
Science (Washington DC), 255: 459-462, 1992.
5. Nguyen, K. T., Liu, B., Ueda, K., Pastan, I., Gottesman, M. M., and
Chin, K. v. Transactivation of the human multidrug resistance (MDR1)
gene promoter by p53 mutants. Oncol. Res., 6: 71-77, 1994.
6. Chin, K. V., and Liu, B. Regulation of the multidrug resistance (MDR1)
gene expression. In Vivo, 8: 835-842, 1994.
7. Abraham, I., Hunter, A. J., Sampson, K. E., Smith, S., Gottesman,
M. M., and Mayo, J. K. Cyclic AMP-dependent protein kinase regulates
sensitivity of cells to multiple drugs. Mol. Cell. Biol., 7: 3098-3106, 1987.
8. Abraham, I., Chin, K-V., Gottesman, M. M., Mayo, J., and Sampson,
K. E. Transfection of a mutant regulatory subunit gene of cAMP-depend-
ent protein kinase causes increased drug sensitivity and decreased ex-
pression of P-glycoprotein. Exp. Cell Res., 189: 133-141 ,1990.
9. Chin, K-V., Chauhan, S. S., Abraham, I., Sampson, K. E., Krolczyk,
A. J., Wong, M., Schimmer, B., Pastan, I., and Gottesman, M. M. Reduced
expression of the multidrug-resistant gene in cAMP-dependent protein
kinase mutant cell lines. J. Cell. Physiol., 152: 87-94, 1992.
10. Kim, S., Park, J., Chung, B., Kang, C., and Hidaka, H. Inhibition of
MDR1 gene expression by H-87, a selective inhibitor of cAMP-dependent
protein kinase. Cancer Left., 74: 37-41 ,1993.
11. Daniel, V., Litwack, G., and Tomkins, G. M. Induction of cytolysis of
cultured lymphoma cells by adenosine 3:5-cyclic monophosphate and
the isolation of resistant variants. Proc. NatI. Acad. Sci. USA, 70: 76-79,
1973.
12. Insel, P. A., Boume, H. A., Coffino, P., and Tomkins, G. M. Cyclic
AMP-dependent protein kinase. Pivotal role in regulation of enzyme in-
duction and growth. Science (Washington DC), 190: 896-898, 1975.
1 3. Gottesman, M. M. Genetic approaches to cyclic AMP effects in cul-
tured mammalian cells. Cell, 22: 329-330, 1980.
14. Gottesman, M. M., LeCam, A., Bukowski, M., and Pastan, I. Isolation
of multiple classes of mutants of CHO cells resistant to cyclic AMP.
Somatic Cell Genet., 6: 45-61, 1980.
15. Singh, T. J., Hochman, J., Vema, R., Chapman, M., Abraham, I.,
Pastan, I. H., and Gottesman, M. M. Characterization of a cyclic AMP-
resistant Chinese hamster ovary cell mutant containing both wild-type and
mutant species of type I regulatory subunit of cyclic AMP dependent
protein kinase. J. Biol. Chem., 260: 13927-13933, 1985.
16. Gosse, M. E., Padmanabhan, A., Fleischmann, R. D., and Gottesman,
M. M. Expression of Chinese hamster cAMP-dependent protein kinase in
Escherichia coil results in growth inhibition of bacterial cells: a model for
the rapid screening of mutant type I regulatory subunits. Proc. NatI. Acad.
Sci. USA, 90: 8159-8163, 1993.
17. Evain, D., Gottesman, M. M., Pastan, I., and Anderson, W. B. A
mutation affecting the catalytic subunit of cyclic AMP-dependent protein
kinase in CHO cells. J. Biol. Chem., 254: 6931-6937, 1979.
18. Singh, T. J., Roth, C., Gottesman, M. M., and Pastan, I. H. Charac-
terization of cyclic AMP-resistant Chinese hamster ovary cell mutants
lacking type I protein kinase. J. Biol. Chem., 256: 926-932, 1981.
19. Howard, P., Day, K. H., Kim, K. E., Richardson, J., Thomas, J.,
Abraham, I., Fleischmann, R. D., Gottesman, M. M., and Maurer, R. A.
Decreased catalytic subunit mRNA levels and altered catalytic subunit
mRNA structure in a cAMP-resistant Chinese hamster ovary cell line.
J. Biol. Chem., 266: 10189-10195, 1991.
20. Johnson, G, S., Friedman, A. M., and Pastan, I. Restoration of several
morphological characteristics of normal fibroblasts in sarcoma cells
treated with adenosine-3’:S’-cyclic monophosphate and its derivatives.
Proc. NatI. Acad. Sci. USA, 68: 425-429, 1971.
21 . Pastan, I., and Gottesman, M. Multiple-drug resistance in human
cancer. N. EngI. J. Med., 316: 1388-1393, 1987.
22. Chin, K-V., Pastan, I., and Gottesman, M. M. Function and regulation
of the human multidrug resistance gene. Adv. Cancer Res., 60: 157-180,
1993.
23. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resist-
ance mediated by the multidrug transporter. Annu. Rev. Biochem., 62:
385-427, 1993.
24. North, P. 5., Davies, S. L, Ciardiello, F., Damiano, V., Bianco, C.,
Pepe, S., Bianco, A. R., Harris, A. L, Hickson, I. D., and Tortora, G.
Overexpression of the RIa subunit of protein kinase A confers hypersen-
sitivity to topoisomerase II inhibitors and 8-chloro-cyclic adenosine 3,5’-
monophosphate in Chinese hamster ovary cells. Cancer Res., 54: 4123-
4128, 1994.
25. Scala, S., Budillon, A., Zhan, Z., Cho-Chung, V. S., Jefferson, J.
Tsokos, M., and Bates, S. Downregulation of mdr-1 expression by 8-Cl-
cAMP in multidrug resistant MCF-7 human breast cancer cells. J. Clin.
Invest., 96: 1026-1034, 1995.
26. Rohiff, C., Clair, T., and Cho-Chung, V. S. 8-Cl-cAMP induces trun-
cation and down-regulation of the RIa subunit and up-regulation of the
RlIf3 subunit of cAMP-dependent protein kinase leading to type II holoen-
zyme-dependent growth inhibition and differentiation of HL-60 leukemia
cells. J. Biol. Chem., 268: 5774-5782, 1993.
27. Uu, B., Cvijic, M. E., Jetzt, A., and Chin, K-V. Cisplatin resistance and
regulation of DNA repair in cAMP-dependent protein kinase mutants. Cell
Growth Differ., 7: 1105-1112, 1996.
28. Nishio, K., Morikage, T., Kubota, N., Ohmori, T., Takeda, V., Fujiwara,
V., Miki, K., Abe, K., and Saijo, N. Alteration of type II regulatory subunit
of cAMP-dependent protein kinase in human cisplatin-resistant cells as a
basis of collateral sensitivity to 8-chloro-cAMP. Jpn. J. Cancer Res., 83:
754-760, 1992.
29. Coghlan, V. M., Perrino, B. A., Howard, M., Langeberg, L K., Hicks,
J. B., Gallatin, W. M., and Scott, J. D. Association of protein kinase A and
protein phosphatase 2B with a common anchoring protein. Science
(Washington DC), 267: 108-1 1 1,1995.
30. Constaninou, A. I., Squinto, S. P., and Jungmann, R. A. The phos-
phoform of the regulatory subunit Ril of cyclic AMP-dependent protein
kinase posses intrinsic topoisomerase activity. Cell, 42: 429-437, 1985.
